Prenetics Global Limited (NASDAQ:PRE) shares traded -16.74% lower at $1.89 on Wall Street last session.
In accordance with the data, 2 analysts cover Prenetics Global Limited (NASDAQ:PRE). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $8.10, we find $11.55. Given the previous closing price of $2.27, this indicates a potential upside of 408.81 percent. PRE stock price is now -16.61% away from the 50-day moving average and -56.11% away from the 200-day moving average. The market capitalization of the company currently stands at $209.79M.
It has been rated a hold by 0 analysts and a buy by 2. Brokers who have rated the stock have averaged $11.55 as their price target over the next twelve months.
A total of 31.38% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PRE stock. A new stake in Prenetics Global Limited shares was purchased by VIDENT INVESTMENT ADVISORY, LLC during the first quarter worth $31,000. In total, there are 18 active investors with 9.30% ownership of the company’s stock.
Prenetics Global Limited (NASDAQ: PRE) opened at $2.1100 on Wednesday. During the past 12 months, Prenetics Global Limited has had a low of $1.24 and a high of $8.75. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 5.00, and a quick ratio of 4.90. The fifty day moving average price for PRE is $2.2666 and a two-hundred day moving average price translates $4.3059 for the stock.
The latest earnings results from Prenetics Global Limited (NASDAQ: PRE) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at $0.04, beating analysts’ expectations of -$0.62 by 0.66. This compares to -$2.65 EPS in the same period last year. The net profit margin was -96.40% and return on equity was 278.30% for PRE. The company reported revenue of $79.68 million for the quarter, compared to $74.66 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.73 percent. For the current quarter, analysts expect PRE to generate $66.58M in revenue.
Prenetics Global Limited(PRE) Company Profile
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company’s products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.